WIA
TEVA icon

Wealthstreet Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Wealthstreet Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,233
Closed -$200K – 348
2018
Q2 		$200K Buy
+8,233
New +$168K 0.03% 336

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Wealthstreet Investment Advisors's TEVA Position: Q3 2018 in Review

Wealthstreet Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 8,233 shares — an estimated $200K sold.

Wealthstreet Investment Advisors first reported a position in TEVA in Q2 2018 and held it in 1 quarter. The position peaked at $200K in Q2 2018. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • Wealthstreet Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Wealthstreet Investment Advisors sold 8,233 Teva Pharmaceuticals shares in Q3 2018, an estimated $200K.
  • Wealthstreet Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Wealthstreet Investment Advisors's Teva Pharmaceuticals position peaked at $200K in Q2 2018.
  • 556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Wealthstreet Investment Advisors's 13F filing for Q3 2018, filed 31 Oct 2018.